Table 4. Relationships between CAPRA score and established classification criteria I and II, and final pathology in patients with IRPCa.
| Classifications | Established criteria I | P | Established criteria II | P | Final pathology | P | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Favorable | Unfavorablea | Favorable | Unfavorableb | Favorable | Unfavorablec | |||||
| CAPRA score | < 0.001 | < 0.001 | < 0.001 | |||||||
| 1 | 4 (3.7) | 0 (0) | 3 (4.0) | 1 (0.8) | 1 (0) | 3 (1.8) | ||||
| 2 | 31 (28.7) | 5 (5.3) | 20 (26.7) | 16 (12.5) | 14 (36.8) | 22 (13.3) | ||||
| 3 | 61 (56.5) | 8 (8.4) | 43 (57.3) | 26 (20.3) | 14 (36.8) | 55 (33.3) | ||||
| 4 | 12 (11.1) | 27 (28.4) | 9 (12.0) | 30 (23.4) | 4 (10.5) | 35 (21.2) | ||||
| 5 | 0 (0) | 30 (31.6) | 0 (0) | 30 (23.4) | 3 (7.9) | 27 (16.4) | ||||
| 6 | 0 (0) | 23 (24.2) | 0 (0) | 23 (18.0) | 2 (5.3) | 21 (12.7) | ||||
| 7 | 0 (0) | 2 (2.1) | 0 (0) | 2 (1.6) | 0 (0) | 2 (1.2) | ||||
Values are presented as number (%). P values were obtained by linear-by-linear association.
CAPRA = Cancer of the Prostate Risk Assessment, IRPCa = intermediate-risk prostate cancer.
Unfavorable disease was defined as aprimary Gleason pattern of 4 or ≥ 2 determinant of intermediate-risk factors at biopsy pathology; bcriteria I or percentage of positive biopsy cores ≥ 50%; cGleason score ≥ 7 or locally advanced disease at surgical pathology.